Dual targeting of TAM receptors Tyro3, Axl, and MerTK: Role in tumors and the tumor immune microenvironment

Kai-Hung Wang* and Dah-Ching Ding*

Department of Medical Research, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Hualien, Taiwan, Department of Obstetrics and Gynecology, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation and Tzu Chi University, Hualien, Taiwan

ABSTRACT

In both normal and tumor tissues, receptor tyrosine kinases (RTKs) may be pleiotropically expressed. The RTKs not only regulate ordinary cellular processes, including proliferation, survival, adhesion, and migration, but also have a critical role in the development of many types of cancer. The Tyro3, Axl, and MerTK (TAM) family of RTKs (Tyro3, Axl, and MerTK) plays a pleiotropic role in phagocytosis, inflammation, and normal cellular processes. In this article, we highlight the cellular activities of TAM receptors and discuss their roles in cancer and immune cells. We also discuss cancer therapies that target TAM receptors. Further research is needed to elucidate the function of TAM receptors in immune cells toward the development of new targeted immunotherapies for cancer.

KEYWORDS: Axl, MerTK, Tyro3, Axl, and MerTK receptors, Tumor immune microenvironment, Tyro3

INTRODUCTION

The Tyro3, Axl, and MerTK (TAM) proteins belong to the receptor tyrosine kinase (RTK) subclass of protein kinases. TAMs are ligand-activated transmembrane proteins that mediate signal transduction from an extracellular receptor through the cytoplasm to the nucleus and trigger expression of various oncogenes [1]. Many tyrosine kinase inhibitors (TKIs) have been synthesized for cancer treatment, and several inhibitors of TAM receptors have been developed for various cancers. The TAM receptors have similar domain structures and functions. Unlike other RTKs, TAM receptors play important roles in tissue conservation, inflammation, and phagocytosis, as well as in cell development, growth, migration, and survival [2,3]. Thus, the deregulation of TAM signaling is linked to various autoimmune diseases and cancers. In this review, we discuss the structure and function of TAM receptors and the roles of their ligands, growth arrest-specific 6 (Gas6), and protein S (ProS) [4]. We also explore the role of TAM receptors in immune cell function and in cancer development. Finally, we discuss TAM receptor inhibitors and their potential roles in the development of new cancer therapies.

CLONING AND GENOMIC STRUCTURE OF TYRO3, AXL, AND MERTK RECEPTORS

Tyro3 was first discovered as a transforming gene in chronic myelogenous leukemia (CML) patients in 1988 [5]. Axl is located on chromosome 19q13.2 and was cloned in 1991 [6]. The next TAM family receptor to be identified was v-ryk, isolated from the avian retrovirus RLP30 [7], followed by cloning of the human analog c-Mer. Expression of c-Mer is found in monocytes and epithelial and reproductive tissues [8]. An alias of Mer is Mer tyrosine kinase (MerTK), located on human chromosome 2q14.1 [9]. Murine Tyro3 [10] and the human analog Tyro3, located on chromosome 15q15 [11], were cloned in 1993. Tyro3 and Axl each have 20 same-sized exons [12], while Mer is encoded by 19 exons [13]. In the tyrosine kinase domain, Mer and Axl share the most similar amino acid sequences [14]. Human TAM receptors share approximately 34% and 57% amino acid sequence identity within the coding regions for the extracellular and intracellular domains, respectively, resulting in high homology in the intracellular tyrosine kinase domain [15]. However, the actual molecular weights of TAMs differ from the predicted protein size due to posttranslational modifications, including ubiquitination, phosphorylation, and glycosylation [6,12,16,17]. These modifications may cause cell- and tissue-type-specific alterations in the regulation of TAM receptor function.

*Address for correspondence:
Dr. Dah-Ching Ding,
Department of Obstetrics and Gynecology, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, 707, Section 3, Chung-Yang Road, Hualien, Taiwan.
E-mail: dah1003@yahoo.com.tw

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

For reprints contact: WKHLRPMedknow_reprints@wolterskluwer.com

How to cite this article: Wang KH, Ding DC. Dual targeting of TAM receptors Tyro3, Axl, and MerTK: Role in tumors and the tumor immune microenvironment. Tzu Chi Med J 2021;33:250-6.
TYRO3, AXL, AND MERTK RECEPTOR PROTEIN STRUCTURE AND ASSOCIATED LIGANDS

TAM receptors are RTKs that are widely expressed in the nervous, immune, vascular, and reproductive systems and regulate cell growth, survival, differentiation, adhesion, and motility. TAM receptors contain two immunoglobulin (Ig)-like domains, two type III fibronectin (FN III) domains within the extracellular domain, and one conserved KW (I/L) A (I/L) ES sequence within the intracellular domain [Figure 1a] [1]. TAM receptor ligands include Vitamin K-dependent Gas6 and ProS, which have similar domain structures, such as a C-terminal sex hormone-binding globulin, four epidermal growth factor (EGF)-like repeats, and an N-terminal γ-carboxyglutamic acid (Gla)-rich domain. Gas6 and ProS demonstrate Ca2+-dependent binding to phosphatidylserine (PtdSer)-presenting cell membranes carrying a negative charge, and these protein ligands share 43% amino acid sequence identity [18]. In apoptotic cells, the binding of TAM receptor dimers occurs via interaction with paired Gas6 or ProS molecules bound to the interacting cell membrane via PtdSer, thereby forming a tetrameric complex [Figure 1b]. Gas6 can interact with all TAM receptors, while ProS binds MerTK and Tyro3 only [19]. TAM receptors have overlapping expression patterns and functions. However, TAM-deficient and triple gene knockout mice are viable [12]. Among the RTKs, the Tie (Tie1), Tek (Tie2), fibroblast growth factor receptor, vascular endothelial growth factor receptor (VEGFR), and platelet-derived growth factor receptor families contain extracellular domains that include both Ig-like and FNIII domains or an Ig-like domain alone. The MET RTK family (including Met and Ron) is most closely related to TAMs based on amino acid sequence of the kinase domain [14]. MET RTKs can signal through TAM receptors to activate common RTK signaling pathways and achieve functional redundancy [18,20].

Therefore, differences in the extracellular domain versus the intracellular kinase domain lead to distinct effects on cellular function.

BIOLOGICAL FUNCTIONS OF TYRO3, AXL, AND MERTK RECEPTORS

TAM receptors mediate the phagocytosis and engulfment of apoptotic cells, viral infection, homeostasis of blood vessel integrity, autoimmunity, and oncogenic processes [21,22]. In cell biology, apoptotic cell death and subsequent phagocytosis to clear the apoptotic bodies is important to reduce necrosis and intracellular organoid release that may lead to inflammation and autoantibody creation. Loss of TAM receptor function has been linked to autoimmune disease resulting from failure to clear apoptotic cells [23]. TAM receptors, especially MerTK, function as bridges between phagocytes (e.g., macrophages and dendritic cells) and the apoptotic cells that they engulf. MerTK is expressed on the phagocytes and binds the ligands linked to the PtdSer-presenting apoptotic cells [Figure 1b] [24]. Intriguingly, enveloped viruses present PtdSer residues, mimicking apoptotic cells, and infect innate immune cells, resulting in decreased expression of type I interferon (IFN) [25]. Blockage of TAM receptors impairs the infectivity of viruses such as dengue, West Nile, Ebola, and Zika and reduces viral replication in dendritic cells [26-28]. TAM receptors also function as pleiotropic inhibitors of immune cells [29]. Reduced TAM signaling through down-regulation of ProS may contribute to the progression of autoimmune diseases, including multiple sclerosis and systemic lupus erythematosus [30,31]. Furthermore, TAM receptors, especially Axl and MerTK, are highly expressed in various cancers, driving conventional RTK signaling and playing an oncogenic role [2]. Downstream signaling molecules of TAM receptors include PI3K-Akt-mTOR, MEK-ERK, p38, FAK, STAT5, NFκB, and other proteins that regulate cell proliferation, migration, survival, epithelial–mesenchymal transition (EMT), and chemoresistance [3,32-37]. The functions of TAM receptors are both in regulating cancer cells and immune cells, which provide as good dual targets for cancer drug development.

TYRO3, AXL, AND MERTK RECEPTORS IN CANCER

TAM receptors have been linked to various types of cancer. The expression and role of Axl has been studied extensively, whereas data on the role of Tyro3 in cancer are scarce. Axl is overexpressed in most solid tumors and hematologic malignancies, and MerTK overexpression has been observed in breast, gastric, glioblastoma, lung, and prostate cancers, as well as melanoma and multiple myeloma. Overexpression of Tyro3 only occurred in select hematopoietic malignancies, such as acute myeloid leukemia and multiple myeloma [Table 1]. Among the TAM receptors, Axl is a risk factor for poor prognosis, including lymph node metastasis, reduced disease-free survival, and reduced overall survival in various types of cancer [Table 1]. In addition, activation of TAM receptors suppresses pro-inflammatory cytokines and decreases inflammation, creating an immune-tolerant environment for tumor
Table 1: Association of Tyro3, Axl, and MerTK receptors in cancers

| Cancer types | Axl | MerTK | Tyro3 | Associated outcomes | References |
|--------------|-----|-------|-------|---------------------|------------|
| Breast       | +   |       |       | Axl: poor prognosis, metastasis | [38-41]    |
| Colorectal   | +   |       |       | Axl: poor prognosis           | [42]       |
| Gastric      | +   |       |       | Axl and MerTK: poor prognosis | [43,44]    |
| GBM          | +   |       |       | Axl: poor prognosis           | [45,46]    |
| H and N      |     |       |       | Axl: poor prognosis, metastasis | [47,48]    |
| Lung         |     |       |       | Axl: poor prognosis           | [49,50]    |
| Melanoma     | +   |       |       | Axl: poor prognosis, metastasis | [51-53]    |
| Ovarian      |     |       |       | Axl: poor prognosis           | [54-56]    |
| Pancreatic   |     |       |       | Axl: poor prognosis           | [57,58]    |
| Prostate     |     |       |       | Axl: poor prognosis           | [59]       |
| RCC          |     |       |       | Axl: drug resistance          | [60,61]    |
| AML          |     |       | +     | Axl: poor prognosis, drug resistance | [62-64]    |
| Multiple myeloma |     |       | +     | Axl: poor prognosis           | [65-67]    |

AML: Acute myeloid leukemia, HCC: Hepatocellular carcinoma, H and N: Head and neck cancer, GBM: Glioblastoma, RCC: Renal cell carcinoma

growth [70]. The oncogenic role of TAM receptors is well studied, with supportive evidence in various types of cancer. Furthermore, the inhibitors of TAM receptors, especially Axl, are under developing for treating cancers.

**TYRO3, AXL, AND MERTK RECEPTORS IN IMMUNE CELLS AND THE TUMOR MICROENVIRONMENT**

TAM receptors are also play an important role in certain immune cells, including dendritic cells, macrophages, nature killer (NK) cells, and platelets [1]. TAM-deficient NK cells demonstrated poor cytotoxic activity, 10-fold lower than normal NK cells, and have a lower number of NK cells, indicating that TAM receptors could regulate NK cell differentiation [71]. TAM receptors have been shown to inhibit Toll-like receptor-induced proinflammatory cytokines, including interleukin-6 (IL-6), tumor necrosis factor (TNF), type I IFNs, and IL-12, driving the transition to an immunosuppressive state [23]. As indicated above, loss of TAM receptors in macrophages caused decreased clearance of apoptotic cells, as TAM receptors on macrophages interact with Gas6-linked apoptotic cells and mediate phagocytosis. These phagocytosis phenomena or so-called efferocytosis could further promote M2 polarization of macrophages by secreting IL-10, IL-4, and TGF-β and contribute to tumor progression. On the other hand, the M1 polarization cytokines, TNF-α, IL-1, and IL-12, were decreased, and subsequently reduced the antitumor activity of M1 macrophages [72]. Furthermore, activation of Axl by Gas6 binding can increase the suppressive function of regulatory T cells (Treg) through upregulation of forkhead box P3 expression in vitro and in vivo [73]. Even though studies have shown that TAM receptors play an important role in immune system function, there has been little research into the immunological effects of TAM receptor inhibitors in cancer. So far, we know that inhibition of MerTK significantly increased inflammatory cytokines in serum and increased the number of cytotoxic cells in the TME [74]. In addition, mature NK cells were shown to express TAM receptors, and upon ligand (Gas6) activation, NK cell proliferation and IFNγ production were suppressed [75]. Furthermore, Gas6 secreted from tumor-educatedstromal cells resulted in negative regulation of antitumor immunity, contributing to tumor progression [76]. In contrast, inhibition of TAM receptors showed a pro-tumorigenic effect in colitis-driven colorectal cancer [77]. Nevertheless, inhibition of TAM receptors is needed as a mechanism to control the side effects of excessive inflammation and other immune disorders associated with cancer therapy. In summary, the research of the role of TAM receptors on tumor-associated macrophages, NK cells, dendritic cells, and T cells in cancer TME are needed to further elucidated.

**TYRO3, AXL, AND MERTK RECEPTOR INHIBITORS**

Since the concept of TKIs was raised in 1988, which was focus on epidermal growth factor receptor (EGFR) [78]. However, the first TKI drug was imatinib, which is on the market for treating CML in 2001 [79]. Henceforth, the TKI drugs among targets, such as HER2, VEGF, FGF, PDGF, MET, c-kit, ALK, and second or third generation of them, are under development worldwide. TAM receptors belong to RTK. MerTK and Axl have been studied as therapeutic targets in various cancers, but more research is needed to assess these TAMs relative to tumor-associated macrophages and other cells, particularly immune cells in the TME. There are some TAM inhibitors under development in the preclinical stage and in each stage of clinical trial [Table 2]. Many inhibitors are used to block Axl and/or MerTK, but they also have inhibitory effects on other RTKs, such as VEGFR, c-Met, and Flt3, leading to reduced cell proliferation, migration, and other properties of tumor progression in vitro and in a mouse xenograft model; the next step is to advance testing via clinical trials. In addition to small molecules, several anti-Axl monoclonal antibodies, such as YW327.62S [111] and 20G7-D9 [112], and nucleotide aptamers, e.g., GL21.T [113], are under investigation at the preclinical stage. Thus, TAM inhibitors have great potential as cancer therapy; however, the associated effects on immune cells are limiting. Recently, a newly synthesized small molecule (UNC4241) has been shown to inhibit both TAM receptors and myeloid-derived suppressor cells, thereby enhancing anti-PD-1 therapy for
Table 2: Development of the inhibitors of Tyro3, Axl, and MerTK receptors

| Inhibitor                  | IC50 (nM) | Other targets | Clinical phase | References |
|----------------------------|-----------|---------------|----------------|------------|
| Amuvatinib (MP-470)        | 10        | c-kit, PDGFR, Flt3, RET | Phase 2       | [80,81]    |
| Bemcentinib (R428, BGB324) | 14        |               | Phase 2       | [82,83]    |
| Bosutinib (SKI-606)        |           | Src, Abl      | Phase 2       | [84,85]    |
| Cabozantinib (XL184)       | 7         | VEGFR2, c-Met, c-kit, Flt3 | Phase 3     | [86-89]    |
| Dubermatinib (TP-0903)     | 27        |               | Phase 2       | [90]       |
| Foretinib (XL880)          | 11        | VEGFR2, c-Met, Tie-2, Ron | Phase 2     | [91]       |
| Gilteritinib (ASPI215)     | 0.73      | Flt3          | Phase 3       | [92,93]    |
| Glesatinib (MGCD265)       |           | c-Met, VEGFR1/2/3, Ron | Phase 2     | [94,95]    |
| Merestinib (LY2801653)     | 11        | c-Met, TEK, Ron | Phase 2       | [96,97]    |
| Sitravatinib (MGCD516)     | 1.5       | DDR2, EPHA3, Flt4 | Phase 2       | [98]       |
| BMS 777607                 | 1.1       | c-Met, Ron    | Phase 2       | [99,100]   |
| CEP-40783 (RXDX-106)       | 7         | c-Met         | Phase 1       | [101]      |
| LDC1267                    | 29<5      | c-Met, Aurora B, LCK | Preclinical | [75]       |
| NPS-1034                   | 10.3      | c-Met         | Preclinical    | [102]      |
| S49076                     | 7         | c-Met, FGFR1/2/3 | Phase 1       | [104]      |
| SGI-7079                   | 14        | Flt3          | Lead compound | [107]      |
| UNCl2025                   | 1.7       |               | Lead compound | [108]      |
| UNCl2541                   | 4.4       |               | Lead compound | [109]      |
| UNCl2881                   | 22        |               | Lead compound | [110]      |

Figure 2: Dual targeting of the inhibitors of Tyro3, Axl, and MerTK receptors. Left panel: The drug effects on cancer cells. Right panel: The drug effects on tumor immune microenvironment.

Table contents:
- **Inhibitor**: Name of the inhibitor.
- **IC50 (nM)**: Half-maximal inhibitory concentration in nanomolar.
- **Other targets**: Other targets inhibited by the inhibitor.
- **Clinical phase**: Phase of clinical trial.
- **References**: References for the inhibitor.

**Conclusion**

Overexpression of TAM receptors and their ligands, Gas6 and ProS, has been strongly linked to the growth of various cancers through regulation of cell proliferation, migration, EMT, chemoresistance, and angiogenesis. On the other hand, TAM receptors function as pleiotropic inhibitors of immune cells, regulating phagocytic clearance of apoptotic cells and limiting cytokine release, which may make the TME a more tumor-favorable niche. Initial studies of TAM inhibitors for cancer therapy showed antitumor benefits, but further study is necessary to determine the full immunologic consequences. Future research may also explore combination treatments, sequence of administration, and other considerations of therapeutic strategy to fully realize the potential benefits of TAM inhibitors in the era of individualized targeted cancer therapy.

**Perspective**

The inhibitory drugs of TAM receptors are under development, mostly due to the oncogenic role in the cancer progression. Indeed, blockage of TAM receptors could reduce cancer cell proliferation, migration, invasion, and tumor growth. Moreover, the effect of these drugs may not only inhibit tumor growth itself but also from TME. Inhibition of TAM receptors could decrease immunosuppressive activity, which affects macrophages, NK cells, and Treg cells. However, the side effects of the anti-immunosuppression and auto-immune diseases are needed to further consider in the future. Besides, those TKIs may also inhibit other RTK targets, which is sharing similar structures with TAM receptors. In summary, the dual targeting inhibitors of TAM receptors have great potential for treating various types of cancer [Figure 2].

**Acknowledgment**

We thank Editage for English editing.

**Financial support and sponsorship**

This work was supported by the Buddhist Tzu Chi Medical Foundation (EP-108-02).
References

1. Linger RM, Keating AK, Earp HS, Graham DK. TAM receptor tyrosine kinases: Biologic functions, signaling, and potential therapeutic targeting in human cancer. Adv Cancer Res 2008;100:35-83.

2. Cummings CT, Derycke D, Earp HS, Graham DK. Molecular pathways: MERTK signaling in cancer. Clin Cancer Res 2013;19:5275-80.

3. Li Y, Ye X, Tan C, Hongo JA, Zha J, Liu J, et al. Axl as a potential therapeutic target in cancer: Role of Axl in tumor growth, metastasis and angiogenesis. Oncogene 2009;28:3442-55.

4. Nagata K, Ohashi K, Nakano T, Arita H, Zong C, Hanafusa H, et al. Identification of the product of growth arrest-specific gene 6 as a common ligand for Axl, Sky, and Mer receptor tyrosine kinases. J Biol Chem 1996;271:30022-7.

5. Liu E, Hjelle B, Bishop JM. Transforming genes in chronic myelogenous leukemia. Proc Natl Acad Sci U S A 1988;85:1952-6.

6. O’Bryan JP, Frye RA, Cogswell PC, Neubauer A, Kitch B, Prokop C, et al. Axl, a transformation gene isolated from primary human myeloid leukemia cells, encodes a novel receptor tyrosine kinase. Mol Cell Biol 1991;11:5016-31.

7. Jia R, Mayer BJ, Hanafusa T, Hanafusa H. A novel oncogene, v-ryk, encoding a truncated receptor tyrosine kinase is transduced into the RPL30 virus without loss of viral sequences. J Virol 1992;66:5975-87.

8. Graham DK, Dawgson TL, Mullaney DL, Snodgrass HR, Earp HS. Cloning and mRNA expression analysis of a novel human protooncogene, c-mer. Cell Growth Different 1994;5:647-57.

9. Weier HU, Fung J, Lersch RA. Assignment of protooncogene MERTK (a.k.a. c-mer) to human chromosome 2q14.1 by in situ hybridization. CytoGenet Cell Genet 1999;84:91-2.

10. Biesecker LG, Gottschalk LR, Emerson SG. Identification of four murine cDNAs encoding putative protein kinases from primitive embryonic stem cells differentiated in vitro. Proc Natl Acad Sci U S A 1993;90:7044-8.

11. Polvi A, Armstrong E, Lai C, Lemke G, Huebner K, Spritz RA, et al. The human TYRO3 gene and pseudogene are located in chromosome 15q14-q25. Gene 1993;134:289-93.

12. Lu Q, Gore M, Zhang Q, Camensich T, Boast S, Casagranda F, et al. Tyro-3 family receptors are essential regulators of mammalian spermatogenesis. Nature 1999;398:723-8.

13. Gal A, Li Y, Thompson DA, Weir J, Orth U, Jacobson SG, et al. Mutations in MERTK, the human orthologue of the RCS rat retinal dystrophy gene, cause retinitis pigmentosa. Nat Genet 2000;26:270-1.

14. Robinson DR, Wu YM, Lin SF. The protein tyrosine kinase family of the human genome. Oncogene 2000;19:5548-57.

15. Graham DK, Bowman GW, Dawgson TL, Stanford WL, Earp HS, Snodgrass HR. Cloning and developmental expression analysis of the murine c-mer tyrosine kinase. Oncogene 1995;10:2349-59.

16. Sather S, Kenyon KD, Lefkowitz JB, Liang X, Varnum BC, Henson PM, et al. A soluble form of the Mer receptor tyrosine kinase inhibits macrophage clearance of apoptotic cells and platelet aggregation. Blood 2007;109:1026-33.

17. Válverde P. Effects of Gas6 and hydrogen peroxide in Axl ubiquitination and downregulation. Biochem Biophys Res Commun 2005;333:180-5.

18. Hafizi S, Dahlbäck B. Signalling and functional diversity within the Axl subfamily of receptor tyrosine kinases. Cytokine Growth Factor Rev 2006;17:295-304.

19. Lew ED, Oh J, Burrela PG, Lax I, Zagórska A, Través PG, et al. Differential TAM receptor-ligand-phospholipid interactions delimit differential TAM bioactivities. Elife 2014;3:e03385.

20. Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF. Met, metastasis, motility and more. Nat Rev Mol Cell Biol 2003;4:915-25.

21. Lemke G. Biology of the TAM receptors. Cold Spring Harb Perspect Biol 2013;5:a069076.

22. Lemke G, Rothlin CV. Immunobiology of the TAM receptors. Nat Rev Immunol 2008;8:327-36.

23. Rothlin CV, Ghosh S, Zuniga EI, Oldstone MB, Lemke G. TAM receptors are pietropic inhibitors of the innate immune response. Cell 2007;131:1124-36.

24. Lemke G, Burstyn-Cohen T. TAM receptors and the clearance of apoptotic cells. Annu N Y Acad Sci 2010;1209:23-9.

25. Bhattacharyya S, Zagórska A, Lew ED, Shrestha B, Rothlin CV, Naughton J, et al. Enveloped viruses disable innate immune responses in dendritic cells by direct activation of TAM receptors. Cell Host Microbe 2013;14:136-47.

26. Hamel R, Dejarnac O, Wichit S, Ekchariyawat P, Neyret A, Luplertlop N, et al. Biology of Zika Virus Infection in Human Skin Cells. J Virol 2015;89:8883-96.

27. Meertens L, Carnece X, Leconin MP, Randasi R, Guivel-Benhassine F, Lew E, et al. The TIM and TAM families of phosphatidylserine receptors mediate dendge virus entry cell. Cell Host Microbe 2012;12:544-57.

28. Shimomjia M, Takada A, Ebihara H, Neumann G, Fujioka K, Irimura T, et al. Tyro3 family-mediated cell entry of Ebola and Marburg viruses. J Virol 2006;80:10109-16.

29. Rothlin CV, Carrera-Silva EA, Bosurgi L, Ghosh S. TAM receptor signaling in immune homeostasis. Annu Rev Immunol 2015;33:355-91.

30. Rothlin CV, Lemke G. TAM receptor signaling and autoimmune disease. CurrOpin Immunol 2010;22:740-6.

31. Suh CH, Hilliard B, Li S, Merrill JT, Cohen PL. TAM receptor ligands in lupus: Protein S but not Gas6 levels reflect disease activity in systemic lupus erythematosus. Arthritis Res Ther 2010;12:R146.

32. Antony J, Tan TZ, Kelly Z, Low J, Choolani M, Recchi C, et al. The GAS6-AXL signaling network is a mesenchymal (Mes) molecular subtype-specific therapeutic target for ovarian cancer. Sci Signal 2016;9:ra97.

33. Crittenden MR, Baird J, Friedman D, Savage T, Uhde L, Alice A, et al. MerTK on tumor macrophages is a therapeutic target to prevent tumor recurrence following radiation therapy. Oncotarget 2016;7:78653-66.

34. Schlegel J, Sanibade MJ, Sather S, Moschos SJ, Tan AC, Winges A, et al. MERTK receptor tyrosine kinase is a therapeutic target in melanoma. J Clin Invest 2013;123:2257-67.

35. von Massenhausen A, Sanders C, Thewes B, Deng M, Queisser A, Vogel W, et al. MERTK as a novel therapeutic target in head and neck cancer. Oncotarget 2016;7:32678-94.

36. Wu J, Frady LN, Bash RE, Cohen SM, Schorzman AN, Su YT, et al. MerTK as a therapeutic target in glioblastoma. Neuro Oncol 2018;20:92-102.

37. Yi JH, Jung J, Cho J, Do IJ, Hong M, Kim ST, et al. MerTK is a novel therapeutic target in gastric cancer. Oncotarget 2017;8:96656-67.

38. Gjerdum C, Tiron C, Hosby T, Stefansson I, Haugen H, Sandal T, et al. Axl is an essential epithelial-to-mesenchymal transition-induced regulator of breast cancer metastasis and patient survival. Proc Natl Acad Sci U S A 2010;107:1124-9.

39. Berclaz G, Altermatt HJ, Rohrbach V, Kieffer I, Dreher E, Andres AC. Estrogen dependent expression of the receptor tyrosine kinase axl in normal and malignant human breast. Ann Oncol 2001;12:892-902.

40. Meric F, Lee WP, Sahin A, Zhang H, Kung HJ, Hung MC. Expression profile of tyrosine kinases in breast cancer. Clin Cancer Res 2002;8:361-7.

41. Zanet ND, Walker-Daniels J, Stewart J, Hansen RK, Robinson D, Miao H, et al. MCF-10A-NeoST: A new cell system for studying cell-ECM and cell-cell interactions in breast cancer. Clin Cancer Res 2001;7:3640-8.
42. Craven RJ, Xu LH, Weiner TM, Friddell YW, Dent GA, Srivastava S, et al. Receptor tyrosine kinases expressed in metastatic colon cancer. Int J Cancer 1995;60:791-7.

43. Lin WC, Li AF, Chi CW, Chung WW, Huang CL, Lui WY, et al. Tie-1 protein tyrosine kinase: A novel independent prognostic marker for gastric cancer. Clin Cancer Res 1999;5:1745-51.

44. Wu CW, Li AF, Chi CW, Lai CH, Huang CL, Lo SS, et al. Clinical significance of AXL kinase family in gastric cancer. Anticancer Res 2002;22:1071-8.

45. Hutterer M, Knyazev P, Abate A, Reschke M, Maier H, Stefanova N, et al. Axl and growth arrest-specific gene 6 are frequently overexpressed in human gliomas and predict poor prognosis in patients with glioblastoma multiforme. Clin Cancer Res 2008;14:130-8.

46. Vajkoczy P, Knyazev P, Kunkel A, Capelle HH, Behndt S, von Tengg-Kobligk H, et al. Dominant-negative inhibition of the Axl receptor tyrosine kinase suppresses brain tumor cell growth and invasion and prolongs survival. Proc Natl Acad Sci U S A 2006;103:5799-804.

47. Brand TM, Iida M, Stein AP, Corrigan KL, Braverman CM, Coan JP, et al. AXL is a Logical Molecular Target in Head and Neck Squamous Cell Carcinoma. Clin Cancer Res 2015;21:2601-12.

48. Hector A, Montgomery EA, Karikari C, Canto M, Dunbar KB, Wang JS, et al. The Axl receptor tyrosine kinase is an adverse prognostic factor and a therapeutic target in esophageal adenocarcinoma. Cancer Biol Ther 2010;10:1009-18.

49. Tsou AP, Wu KM, Toen TY, Chi CW, Chiu JH, Lui WY, et al. Parallel hybridization analysis of multiple protein kinase genes: Identification of gene expression patterns characteristic of human hepatocellular carcinoma. Genomics 1998;50:331-40.

50. Liu J, Wang K, Yan Z, Xia Y, Li J, Shi L, et al. Axl expression stratifies patients with poor prognosis after hepatectomy for hepatocellular carcinoma. PLoS One 2016;11:e0154767.

51. Sheih YS, Lai CY, Kao YR, Shiah SG, Chu YW, Lee HS, et al. Expression of axl in lung adenocarcinoma and correlation with tumor progression. Neoplasia 2005;7:1058-64.

52. Zhang Z, Lee JC, Lin L, Olivas V, Au V, Laframboise T, et al. Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer. Nat Genet 2012;44:852-60.

53. Ishikawa M, Sonobe M, Nakayama E, Kobayashi M, Kikuchi M, Kitamura J, et al. Higher expression of receptor tyrosine kinase Axl, and differential expression of its ligand, Gas6, predict poor survival in lung adenocarcinoma patients. Ann Surg Oncol 2013;20 Suppl 3:S467-76.

54. Tirosh I, Izar B, Prakash SM, Wadsworth MH 2nd, Treacy D, Trombetta JJ, et al. Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq. Science 2016;352:189-96.

55. Müller J, Krijgsman O, Tsai J, Robert L, Hugo W, Song C, et al. Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma. Nat Commun 2014;5:5712.

56. van Ginkel PR, Treacy D, Shearer DL, Subramanian L, Walker TM, Albert DM, et al. Expression of the receptor tyrosine kinase Axl promotes ocular melanoma cell survival. Cancer Res 2004;64:1236-40.

57. Chen PX, Li QY, Yang Z. Axl and prostasin are biomarkers for prognosis of ovarian adenocarcinoma. Ann Diagn Pathol 2013;17:425-9.

58. Rea K, Pinciroli P, Sensi M, Aliciato F, Bisaro B, Lozneanu L, et al. Novel Axl-driven signaling pathway and molecular signature characterize high-grade ovarian cancer patients with poor clinical outcome. Oncotarget 2015;6:30859-75.

59. Kooistra JB, Karikari CA, Feldmann G, Bishs S, Rojas PL, Offerhaus GJ, et al. The Axl receptor tyrosine kinase confers an adverse prognostic influence in pancreatic cancer and represents a new therapeutic target. Cancer Biol Ther 2009;8:618-26.

60. Lin JZ, Wang JZ, De W, Zheng M, Xu WZ, Wu HF, et al. Targeting AXL overcomes resistance to docetaxel therapy in advanced prostate cancer. Oncotarget 2017;8:41064-77.

61. Mahajan NP, Whang YE, Mohler JL, Earp HS. Activated tyrosine kinase Axl promotes prostate tumorigenesis: Role of Axl in polyubiquitination of tumor suppressor Wox5. Cancer Res 2005;65:10514-23.

62. Chung BI, Malkowiec SB, Nguyen TB, Libertino JA, McGarvey TW. Expression of the proto-oncogene Axl in renal cell carcinoma. DNA Cell Biol 2003;22:533-40.

63. Gustafsson A, Martuszewska D, Johansson M, Ekman C, Hafizi S, Ljungberg B, et al. Differential expression of Axl and Gas6 in renal cell carcinoma reflecting tumor advancement and survival. Clin Cancer Res 2009;15:4742-9.

64. Zhou L, Liu XD, Sun M, Zhang X, German P, Bai S, et al. Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma. Oncogene 2016;35:2687-97.

65. Neubauer A, Fiebeler A, Graham DK, O’Bryan JP, Schmidt CA, Barckow P, et al. Expression of axl, a transforming receptor tyrosine kinase, in normal and malignant hematopoiesis. Blood 1994;84:1931-41.

66. Rochlitz C, Lohri A, Bacchi M, Schmidt M, Nagel S, Fopp M, et al. Axl expression is associated with adverse prognosis and with expression of Bel-2 and CD34 in de novo acute myeloid leukemia (AML): Results from a multicenter trial of the Swiss Group for Clinical Cancer Research (SAKK). Leukemia 1999;13:1352-8.

67. Hong CC, Lay JD, Huang JS, Chong AL, Tang JL, Lin MT, et al. Receptor tyrosine kinase AXL is induced by chemotherapy drugs and overexpression of AXL confers drug resistance in acute myeloid leukemia. Cancer Lett 2008;268:314-24.

68. Waizengger JS, Ben-Batalla I, Weinhold N, Meissner T, Wohlbewies M, Janning M, et al. Role of Growth arrest-specific gene 6-Mer axis in multiple myeloma. Leukemia 2015;29:696-704.

69. Khoo WH, Lederger G, Weiner A, Roden DL, Terry RL, McDonald MM, et al. A niche-dependent myeloid transcriptome signature defines dormant myeloma cells. Blood 2019;134:30-43.

70. Levin PA, Brekken RA, Byers LA, Heymach JV, Gerber DE. Axl receptor axis: A new therapeutic target in lung cancer. J Thorac Oncol 2016;11:1357-62.

71. Caraux A, Lu Q, Fernandez N, Riou S, Di Santo JP, Raulet DH, et al. Natural killer cell differentiation driven by Tyro3 receptor tyrosine kinases. Nat Immunol 2006;7:747-54.

72. Stanford JC, Young C, Hicks D, Owens P, Williams A, Vaught DB, et al. Efferocytosis produces a prometastatic landscape during postpartum mammary gland involution. J Clin Invest 2014;124:4737-52.

73. Zhao GJ, Zhong YJ, Bian JL, Chen LW, Dong N, Yu Y, et al. Growth arrest-specific 6 enhances the suppressive function of CD4(+) CD25(+) regulatory T cells mainly through Axl Receptor. Mediators Inflamm 2017;2017:6848430.

74. Cook RS, Jacobsen KM, Wofford AM, DeRyckere D, Stanford J, Prieto AL, et al. Met6K inhibition in tumor leukocytes decreases tumor growth and metastasis. J Clin Invest 2013;123:3231-42.

75. Paolino M, Choidas A, Wallner S, Prittie B, Uribesalgo I, Loeser S, et al. The E3 ligase Cbl-b and TAM receptors regulate cancer metastasis in vivo via natural killer cells. Nature 2014;507:508-12.

76. Loges S, Schmidt T, Tjwa M, van Geyte K, Lieve D, Lugten S, et al. Malignant cells fuel tumor growth by educating infiltrating leukocytes to produce the mitogen Gas6. Blood 2010;115:2264-73.

77. Rothlin CV, Leighton JA, Ghose S, Tyro3, Axl, and Mertk receptor signaling in inflammatory bowel disease and colitis-associated cancer. Inflamm Bowel Dis 2014;20:1472-80.

78. Yaish P, Gazit A, Gilon C, Levitzki A. Blocking of EGF-dependent cell proliferation by EGF receptor kinase inhibitors. Science 1988;242:933-5.

79. Traxler P, Bold G, Buchdunger E, Caravatti G, Furet P, Manley P, et al. Tyrosine kinase inhibitors: From rational design to clinical trials. Med Res Rev 2001;21:499-512.

80. Mahadevan D, Cooke L, Riley C, Swart R, Simons B, Della Croce K, et al. A novel tyrosine kinase switch is a mechanism of imatinib resistance
in gastrointestinal stromal tumors. Oncogene 2007;26:3909-19.

81. Mita M, Gordon M, Rosen L, Kapoor N, Choy G, Redkar S, et al. Phase 1B study of amnatinib in combination with five standard cancer therapies in adults with advanced solid tumors. Cancer Chemother Pharmacol 2014;74:195-204.

82. Sheridan C. First Axl inhibitor enters clinical trials. Nat Biotechnol 2013;31:775-6.

83. Holland SJ, Pan A, Franci C, Hu Y, Chang B, Li W, et al. R428, a selective small molecule inhibitor of Axl kinase, blocks tumor spread and prolongs survival in models of metastatic breast cancer. Cancer Res 2016;76:1544-54.

84. Lee HJ, Jeng YM, Chen YL, Cheng L, Yuan RH. Gas6/Axl pathway promotes tumor invasion through the transcriptional activation of Slug in hepatocellular carcinoma. Carcinogenesis 2014;35:769-75.

85. Hino M, Matsumura I, Fujisawa S, Ishizawa K, Ono T, Sakaia E, et al. Phase 2 study of bosutinib in Japanese patients with newly diagnosed chronic phase chronic myeloid leukemia. Int J Hematol 2020;112:24-32.

86. Yakes FM, Chen J, Tan J, Yanaguchi K, Shi Y, Yu P, et al. Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. Mol Cancer Ther 2011;10:2298-308.

87. Kurzrock R, Sherman SI, Ball DW, Forastiere AA, Cohen RB, Mehra R, et al. Activity of XL184 (Cabozantinib), an oral MET kinase inhibitor, in patients with mediulary thyroid cancer. J Clin Oncol 2011;29:2660-6.

88. Zhang Y, Guessed F, Koffman A, Schif D, Abounader R, XL-184, a MET, VEGFR-2 and RET kinase inhibitor for the treatment of thyroid cancer, glioblastoma multiforme and NSCLC. IDrugs 2010;13:112-21.

89. Wakelee HA, Gettinger SN, Engelman JA, Janne PA, West HJ, Subramaniam DS, et al. A phase Ib II study of XL184 (BMS 907351) with and without erlotinib (E) in patients (pts) with non-small cell lung cancer (NSCLC). J Clin Oncol 2010;28 (15 suppl):3017.

90. Aveic S, Corallo D, Porcù E, Pantile M, Boso D, Zanon C, et al. TP-0903 inhibits neuroblastoma cell growth and enhances the sensitivity to Taxol. J Pharmacol 2014;74:195-204.

91. Liu L, Gregor J, Shi H, Liu Y, Greshock J, Annan R, et al. Novel mechanism of laptinib resistance in HER2-positive breast tumor cells: Activation of AXL. Cancer Res 2009;69:6871-8.

92. Park IK, Mishra A, Chandler J, Whitman SP, Marucci G, Caligiuri MA. Inhibition of the receptor tyrosine kinase AXL impedes activation of the FLT3 internal tandem duplication in human acute myeloid leukemia: Implications for Axl as a potential therapeutic target. Blood 2013;121:2064-73.

93. Usuki K, Sakura T, Kobayashi Y, Miyamoto T, Iida H, Morita S, et al. Clinical profile of gilteritinib in Japanese patients with relapsed/refractory acute myeloid leukemia: Implications for Axl as a potential therapeutic target. Blood 2013;121:2064-73.

94. Padda S, Neal JW, Wakelee HA. MET inhibitors in combination with other therapies in non-small cell lung cancer. Transl Lung Cancer Res 2012;1:238-53.

95. Besterman JM, Fournel M, Dupont I, Bonfillis C, Dubay M, Ste-Croix H, et al. Potent preclinical antitumor activity of MGCD265, an oral Met/VEGFR kinase inhibitor in phase II clinical development, in combination with taxanes or erlotinib. J Clin Oncol 2010;28:e13595.

96. Wu W, Bi C, Credille KM, Manro JR, Peck VL, Donoho GP, et al. Inhibition of tumor growth and metastasis in non-small cell lung cancer by LY2801653, an inhibitor of several onco kinases, including MET. Clin Cancer Res 2013;19:6599-710.

97. Yan SB, Peck VL, Ajamie R, Buchanan SG, Graff JR, Heidler SA, et al. LY2801653 is an orally bioavailable multi-kinase inhibitor with potent activity against MET, MST1R, and other oncoproteins, and displays anti-tumor activities in mouse xenograft models. Invest New Drugs 2013;31:833-44.

98. Patwardhan PP, Ivy KS, Musi E, de Stanchina E, Schwartz GK. Significant blockade of multiple receptor tyrosine kinases by MGCD516 (Sitarvatinnib), a novel small molecule inhibitor, shows potent anti-tumor activity in preclinical models of sarcoma. Oncotarget 2016;7:4093-109.

99. Schroeder GM, An Y, Cai ZH, Chen XT, Clark C, Cornelius LA, et al. Discovery of N-(4-2-amino-3-chloropyridin-4-yl)-4-(3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropridine-3-carboxamide (BMS-776707), a selective and orally efficacious inhibitor of the Met kinase superfamily. J Med Chem 2009;52:1251-4.

100. Onken J, Torka R, Korsing S, Radke J, Kremestekaia I, Nieminen M, et al. Inhibiting receptor tyrosine kinase AXL with small molecule inhibitor BMS-776707 reduces glioblastoma growth, migration, and invasion in vitro and in vivo. Oncotarget 2016;7:9876-89.

101. Kim JE, Kim Y, Li G, Kim ST, Kim K, Park SH, et al. MetTK inhibition by RXDX-106 in MetTK activated gastric cancer cell lines. Oncotarget 2017;8:105727-34.

102. Rho JK, Choi YJ, Kim SY, Kim TW, Choi EK, Yoon SJ, et al. MET and AXL inhibitor NPS-1034 exerts efficacy against lung cancer cells resistant to EGFR kinase inhibitors because of MET or AXL activation. Cancer Res 2014;74:253-62.

103. Kimani SG, Kumar S, Bansal N, Singh K, Khelodovyvych V, Comollo T, et al. Small molecule inhibitors block Gas6-inducible TAM activation and tumorigenicity. Sci Rep 2017;7:43908.

104. Burbridge MF, Bossard CJ, Saunier C, Fejes I, Bruno A, Leónce S, et al. S49076 is a novel kinase inhibitor of MET, AXL, and FGFR with strong preclinical activity alone and in association with bevacizumab. Mol Cancer Ther 2013;12:1749-62.

105. Wang X, Saso H, Iwamoto T, Xia W, Gong Y, Pusztai L, et al. TGI promotes the development and progression of inflammatory breast cancer through activation of Axl kinase. Cancer Res 2013;73:6516-25.

106. Byers LA, Diao L, Wang J, Saintigny P, Girard L, Peyton M, et al. An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance. Clin Cancer Res 2013;19:279-90.

107. Zhang W, DeRyckere D, Hunter D, Liu J, Stashko MA, Minson KA, et al. UNC2025, a potent and orally bioavailable MER/FLT3 dual inhibitor. J Med Chem 2014;57:7031-41.

108. Zhang W, Zhang D, Stashko MA, DeRyckere D, Hunter D, Kireev D, et al. Pseudo-cyclization through intramolecular hydrogen bond enables discovery of pyridine substituted pyrimidines as new Mer kinase inhibitors. J Med Chem 2013;56:9683-92.

109. McIver AL, Zhang W, Liu Q, Jiang X, Stashko MA, Nichols J, et al. Discovery of Macrocyclic Pyrimidines as MerTK-Specific Inhibitors. ChemMedChem 2017;12:207-13.

110. Zhang W, McIver AL, Stashko MA, DeRyckere D, Branchford BR, Hunter D, et al. Discovery of Mer specific tyrosine kinase inhibitors for the treatment and prevention of thrombosis. J Med Chem 2013;56:9693-700.

111. Ye X, Li Y, Stawicki S, Couto S, Eastham-Anderson J, Kallop D, et al. An anti-Axl monoclonal antibody augments xenograft tumor growth and enhances the effect of multiple anticancer therapies. Oncogene 2010;29:5254-64.

112. Leconet W, Chentouf M, du Manoir S, Chevalier C, Sirvent A, Aït-Arsou I, et al. Therapeutic activity of anti-AXL antibody against triple-negative breast cancer patient-derived xenografts and metastasis. Clin Cancer Res 2017;23:2806-16.

113. Cerchia L, Esposito CL, Camorani S, Rienzo A, Torka R, et al. Targeting Axl with an high-affinity inhibitory aptamer. Mol Ther 2012;20:2291-303.

114. Holzhausen A, Harris W, Ubl E, Hunter DM, Zhao J, Zhang Y, et al. TAM family receptor kinase inhibition reverses MDSC-mediated suppression and augments anti-PD-1 therapy in melanoma. Cancer Immunol Res 2019;7:1672-86.